eoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis

Phase 2

• Conditions: colorectal cancer with liver metastasis

• Registration Number: JPRN-UMIN000005381
• Lead Sponsor: Tokushima university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-04-07
• Study Completion: 2014-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1)had a previous serious medical illness or allergy for drugs 2)had active double cancer 3)had a hypersensitivity or taboo for test drugs 4)had active infection disease(oner 38.0C fever) 5)had serious complication(ireus,renal function,liver function,heart failure,diabetes within could not control) 6)had serious bowel blockage 7)had serious interstitinal fibrosis 8)had pleural effusion or abdominal dropsy within could not control 9)had watersolubility diarrhea 10)had brain metastasis 11)pregnant or lactating woman,woman who are capable of pregnancy or intend to get pregnant,man who are not inend to contraception 12)had mental illness 13)expect referred to above physician in charge of this trial gave a diagnosis the patient who can not join this trial for the safety

Study & Design

• Study Type: Interventional
• Study Design: Not specified